Having close ties to his home country- Israel, Pfizer CEO Albert Bourla revealed on Saturday night that the pharma giant is now working on developing a one-shot annual vaccine to replace its current vaccine, which loses its efficacy after three to six months and requires multiple booster shots.
Speaking to Israel’s Channel 12, Bourla said that getting jabbed every four or five months “will not be a good scenario” and that having an annual shot, similar to the flu vaccine, “from a public health perspective, it is an ideal situation.”
While on the news channel, he also noted that Pfizer is still on target to have an Omicron-specific vaccine by March and that the company is also evaluating other types of offerings, including taking a fourth dose of the existing vaccine, increasing vaccine dosage and even a hybrid Delta-Omicron shot.
Speaking about the annual shot, he said, “’Once a year – it is easier to convince people to do it. It is easier for people to remember. So from a public health perspective, it is an ideal situation. We are looking to see if we can create a vaccine that covers Omicron and doesn’t forget the other variants and that could be a solution.”